Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Malignant Lymphoma

  Free Subscription


1 Am J Pathol
3 Blood
2 Br J Dermatol
1 Haematologica
1 J Clin Oncol
2 Leuk Lymphoma
1 N Engl J Med

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Pathol

  1. ZHANG Q, Wang HY, Nayak A, Nunez-Cruz S, et al
    Induction of Transcriptional Inhibitor Hairy and Enhancer of Split Homolog-1 and the Related Repression of Tumor-Suppressor Thioredoxin-Interacting Protein Are Important Components of Cell-Transformation Program Imposed by Oncogenic Kinase Nucleophosm
    Am J Pathol. 2022 May 28. pii: S0002-9440(22)00148.
    PubMed         Abstract available


  2. GHIONE P, Palomba ML, Patel A, Bobillo S, et al
    Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.
    Blood. 2022 Jun 9. pii: 485518. doi: 10.1182/blood.2021014375.
    PubMed         Abstract available

  3. PETERSON JM, Lyapichev KA
    Extranodal natural killer/T-cell lymphoma of the palate.
    Blood. 2022;139:3450.

  4. FERNANDEZ-SEVILLA LM, Valencia J, Ortiz-Sanchez P, Fraile-Ramos A, et al
    High BMP4 expression in low/intermediate risk BCP-ALL identifies children with poor outcomes.
    Blood. 2022;139:3303-3313.
    PubMed         Abstract available

    Br J Dermatol

  5. BATTESTI G, Ram-Wolff C, Dobos G, Aubin F, et al
    Granulomatous slack skin: clinical characteristics, prognosis, and response to therapy. A study from the Cutaneous Lymphoma French Study Group.
    Br J Dermatol. 2022 Jun 6. doi: 10.1111/bjd.21699.

  6. ROELENS M, de Masson A, Andrillon A, Ram-Wolff C, et al
    Mogamulizumab induces long-term immune restoration and reshapes tumour heterogeneity in Sezary syndrome.
    Br J Dermatol. 2022;186:1010-1025.
    PubMed         Abstract available


  7. GALTIER J, Vercellino L, Chartier L, Olivier P, et al
    PET-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T-cells.
    Haematologica. 2022 Jun 9. doi: 10.3324/haematol.2021.280550.
    PubMed         Abstract available

    J Clin Oncol

  8. WANG M, Munoz J, Goy A, Locke FL, et al
    Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
    J Clin Oncol. 2022 Jun 4:JCO2102370. doi: 10.1200/JCO.21.02370.
    PubMed         Abstract available

    Leuk Lymphoma

  9. SEITTER SJ, McClelland PH, Ahlman MA, Goff SL, et al
    Durable remissions in two adult patients with Burkitt lymphoma following anti-CD19 CAR T-cell therapy: a single center experience.
    Leuk Lymphoma. 2022 Jun 9:1-5. doi: 10.1080/10428194.2022.2076853.

  10. ALLEN PB, Goyal S, Switchenko J, Tarabadkar E, et al
    Mitigation strategies among cutaneous T-cell lymphoma patients with positive Staphylococcus aureus skin and soft tissue cultures have unclear impacts on the risk of subsequent bacteremia.
    Leuk Lymphoma. 2022 Jun 7:1-8. doi: 10.1080/10428194.2022.2081324.
    PubMed         Abstract available

    N Engl J Med

  11. WANG ML, Jurczak W, Jerkeman M, Trotman J, et al
    Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
    N Engl J Med. 2022 Jun 3. doi: 10.1056/NEJMoa2201817.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.